SG7 Stock Overview A biopharmaceutical company, develops and commercializes brain health medicines. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Sage Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Sage Therapeutics Historical stock prices Current Share Price US$5.32 52 Week High US$23.60 52 Week Low US$5.29 Beta 0.92 1 Month Change n/a 3 Month Change n/a 1 Year Change n/a 3 Year Change -85.11% 5 Year Change -92.11% Change since IPO -75.76%
Recent News & Updates
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease Nov 20
Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes Oct 20 Sage Therapeutics, Inc. Announces Executive Changes
Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 15
Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease Oct 08 Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Sep 18
See more updates
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease Nov 20
Sage Therapeutics, Inc.'s CFO Kimi Iguchi to Depart Amid Leadership Changes Oct 20 Sage Therapeutics, Inc. Announces Executive Changes
Sage Therapeutics, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 15
Sage Therapeutics Announces Topline Results from the Phase 2 Lightwave Study of Dalzanemdor (Sage-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’S Disease Oct 08 Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Sep 18
Insufficient new directors Sep 12
Holzer & Holzer, LLC Announces a Class Action Lawsuit Has Been Filed Against Sage Therapeutics, Inc Aug 30
New minor risk - Shareholder dilution Aug 02
Second quarter 2024 earnings released: US$1.70 loss per share (vs US$2.68 loss in 2Q 2023) Aug 01
Insufficient new directors Jul 25 Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of Sage-324 (BIIB124) for the Treatment of Essential Tremor Jul 24
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 2500 Growth Index Jul 03
Sage Therapeutics, Inc. Announces Topline Results from the Phase 2 SURVEYOR Study Jun 13
Insufficient new directors May 15
Sage Therapeutics, Inc., Annual General Meeting, Jun 10, 2024 Apr 26
First quarter 2024 earnings released: US$1.80 loss per share (vs US$2.46 loss in 1Q 2023) Apr 25
Sage Therapeutics, Inc. Announces Topline Results from Phase 2 PRECEDENT Study of DalzanemDor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease Apr 17
Sage Therapeutics, Inc. to Report Q1, 2024 Results on Apr 25, 2024 Apr 12
Insufficient new directors Mar 26
Insufficient new directors Feb 16
Sage Therapeutics, Inc. to Report Q4, 2023 Results on Feb 14, 2024 Feb 01
Sage Therapeutics, Inc. Announces Changes to Board of Directors Jan 08
Insufficient new directors Dec 28 Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV Dec 15
Insufficient new directors Dec 01
Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Nov 09 Sage Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $250 million. Nov 08
Sage Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 25
Sage Therapeutics, Inc. Announces U.S. Food and Drug Administration Granted Sage-718 Orphan Drug Designation for the Treatment of Huntington's Disease Oct 19 Sage Therapeutics, Inc. Announces Reduction of the Workforce by Approximately 40%
Second quarter 2023 earnings released: US$2.68 loss per share (vs US$2.13 loss in 2Q 2022) Aug 08 Sage Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023
Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Feb 07
Sage Therapeutics, Inc. to Report Q4, 2022 Results on Feb 16, 2023 Feb 03
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression Dec 07
Sage Therapeutics, Inc. Announces Resignation of Jeffrey M. Jonas as Chief Innovation Officer Nov 09
Sage Therapeutics Appoints Laura M. Gault as Chief Medical Officer Nov 02
Sage Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 Skylark Study of Zuranolone in Postpartum Depression At the European College of Neuropsychopharmacology (Ecnp) Congress Oct 18
Sage Therapeutics, Inc. Enters into Settlement Agreement Jul 16
Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 1000 Dynamic Index Jun 26
Sage Therapeutics, Inc. Provides Zuranolone New Drug Application Update Jun 14
Sage Therapeutics and Biogen Announce that the Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints Jun 02
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) May 03
Sage Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022 Apr 20
Sage Therapeutics Announces Presentation of Promising Results from the Phase 2 Luminary Study of Sage-718 in Patients with Mild Cognitive Impairment and Mild Dementia Due to Alzheimer’s Disease Apr 03
Sage Therapeutics, Inc. Provides Business Update Feb 25
Sage Therapeutics, Inc and Biogen Inc Announce Phase 3 CORAL Study Met its Primary and Key Secondary Endpoints Feb 17
Sage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology Congress Dec 09
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD Dec 02
Third quarter 2021 earnings released: US$2.21 loss per share (vs US$2.03 loss in 3Q 2020) Nov 06
President recently bought €861k worth of stock Aug 11
Second quarter 2021 earnings released: US$1.83 loss per share (vs US$2.63 loss in 2Q 2020) Aug 04 Sage Therapeutics, Inc.(NasdaqGM:SAGE) dropped from Russell 3000E Growth Index
Independent Chairman recently bought €825k worth of stock Jun 18
Sage Therapeutics, Inc. and Biogen Inc. Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder Jun 16
Investor sentiment improved over the past week Jun 11
Sage Therapeutics, Inc. to Host Sage Science Spotlight: SAGE-718 In Depth May 14
First quarter 2021 earnings released: US$1.64 loss per share (vs US$2.44 loss in 1Q 2020) May 05
Chief Operating Officer has left the company May 05
Sage Therapeutics, Inc. Announces Continued Positive Zuranolone Data for Both 30 Mg and 50 Mg Doses in Open-Label SHORELINE Study in Patients with MDD Mar 19
Sage Therapeutics, Inc. Announces Departure of Mike Cloonan as Chief Operating Officer, Effective May 3, 2021 Mar 17
Revenue beats expectations Feb 27
Full year 2020 earnings released: EPS US$11.66 (vs US$13.38 loss in FY 2019) Feb 25
Sage Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021 Feb 11
New 90-day high: €72.48 Jan 09 Sage Therapeutics, Inc. Appoints Barry Greene as President Sage Therapeutics, Inc. Enters into A Collaboration and License Agreement with Biogen Ma Inc. and Biogen International Gmbh
Third quarter 2020 earnings released: US$2.03 loss per share Nov 07
Revenue misses expectations Nov 07
New 90-day high: €66.96 Nov 06
Sage Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020 Oct 20
New 90-day high: €58.04 Oct 19
Sage Therapeutics, Inc. Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD Oct 16
Sage Therapeutics, Inc. Appoints Barry Greene to Board of Directors Oct 02
New 90-day high: €52.60 Sep 28
New 90-day high - €47.57 Sep 11
First half earnings released Aug 10
New 90-day high - €42.39 Aug 06
Sage Therapeutics, Inc. to Report Q2, 2020 Results on Aug 10, 2020 Jul 22 Shareholder Returns SG7 DE Biotechs DE Market 7D 0% -3.5% -2.0% 1Y n/a -14.7% 6.9%
See full shareholder returns
Return vs Market: Insufficient data to determine how SG7 performed against the German Market .
Price Volatility Is SG7's price volatile compared to industry and market? SG7 volatility SG7 Average Weekly Movement n/a Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: SG7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine SG7's volatility change over the past year.
About the Company Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson’s diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington’s disease, Parkinson’s diseases, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain.
Show more Sage Therapeutics, Inc. Fundamentals Summary How do Sage Therapeutics's earnings and revenue compare to its market cap? SG7 fundamental statistics Market cap €328.91m Earnings (TTM ) -€323.55m Revenue (TTM ) €101.97m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SG7 income statement (TTM ) Revenue US$106.40m Cost of Revenue US$265.56m Gross Profit -US$159.16m Other Expenses US$178.44m Earnings -US$337.59m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -5.52 Gross Margin -149.58% Net Profit Margin -317.29% Debt/Equity Ratio 0%
How did SG7 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:38 End of Day Share Price 2024/12/04 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Sage Therapeutics, Inc. is covered by 39 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Esther Lannie Hong Berenberg null null BMO Capital Markets Equity Research
Show 36 more analysts 
